Exploring preventive effects of penehyclidine hydrochloride on postoperative nausea and vomiting during early postoperative period in patients undergoing bariatic surgery: A clinical study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052418

Enrollment

Unknown

Registered

2021-10-25

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Penehyclidine Group:0.5mg penehyclidine hydrochloride

Control Group:the same volume of normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective laparoscopic bariatric surgery, aged 18-65 years, with the American Society of Anesthesiologists (ASA) grade I to III.

Exclusion criteria

Exclusion criteria: Patients with glaucoma, basal ganglia disease, Parkinson's disease, pheochromocytoma, myasthenia gravis, severe central nervous depression; ECG showing prolonged Q-T interval; Antiemetic drugs were used within 48 hours before operation; Neostigmine and atropine can not be used to antagonize residual muscle relaxation.

Design outcomes

Primary

Measure	Time frame
Incidence of PONV;	—

Secondary

Measure	Time frame
The amount of drinking water;the time to first flatus;Severity of PONV;	—

Countries

China

Contacts

Public ContactBo Gui

Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital with Nanjing Medical University

guibosy@163.com+86 13675163272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026